Literature DB >> 18599228

Effect of aggregation state on the toxicity of different amphotericin B preparations.

Raquel Espada1, Suriñe Valdespina, Carlos Alfonso, German Rivas, M Paloma Ballesteros, Juan J Torrado.   

Abstract

The aim of this work was to study the effect of aggregation of amphotericin B (AMB) in their toxicity. The aggregation of AMB depends on different formulation factors such as pH and excipients, therefore three formulations with different AMB aggregation states were prepared: a monomeric form (M-AMB), a dimeric form (D-AMB) and a poly-aggregated form (P-AMB). The predominant aggregation state of each AMB formulation was characterized by spectrophotometry and their size by dynamic laser light scattering. Toxicity was evaluated by lethality in mice and hemolysis test from human erythrocytes and the experimental AMB formulations were compared with reference formulations of AmBisome, Fungizone and heated Fungizone. The less toxic aggregation form of AMB was the poly-aggregated one which was similar to AmBisome. Moreover, the P-AMB and heated Fungizone were centrifuged to isolate different size fractions. The toxicity of these two heterogeneous formulations was related to their size, so the smaller the aggregation size fraction the higher the toxicity determined by hemolysis. It can be concluded that the aggregation state of AMB and their size affects critically the toxicity of AMB. The low toxic P-AMB formulations contain a different poly-aggregated state to that of AmBisome, heated Fungizone and the other studied AMB aggregation states.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18599228     DOI: 10.1016/j.ijpharm.2008.05.013

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  19 in total

1.  Characterization of the colloidal properties, in vitro antifungal activity, antileishmanial activity and toxicity in mice of a di-stigma-steryl-hemi-succinoyl-glycero-phosphocholine liposome-intercalated amphotericin B.

Authors:  Maryam Iman; Zhaohua Huang; Francis C Szoka; Mahmoud R Jaafari
Journal:  Int J Pharm       Date:  2011-01-26       Impact factor: 5.875

2.  Biodistribution and In Vivo Antileishmanial Activity of 1,2-Distigmasterylhemisuccinoyl-sn-Glycero-3-Phosphocholine Liposome-Intercalated Amphotericin B.

Authors:  Maryam Iman; Zhaohua Huang; Seyedeh Hoda Alavizadeh; Francis C Szoka; Mahmoud R Jaafari
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

3.  Accelerated healing of cutaneous leishmaniasis in non-healing BALB/c mice using water soluble amphotericin B-polymethacrylic acid.

Authors:  Karina Corware; Debra Harris; Ian Teo; Matthew Rogers; Kikkeri Naresh; Ingrid Müller; Sunil Shaunak
Journal:  Biomaterials       Date:  2011-07-31       Impact factor: 12.479

4.  Solid lipid nanoparticles of amphotericin B (AmbiOnp): in vitro and in vivo assessment towards safe and effective oral treatment module.

Authors:  Manisha B Chaudhari; Preshita P Desai; Pratikkumar A Patel; Vandana B Patravale
Journal:  Drug Deliv Transl Res       Date:  2016-08       Impact factor: 4.617

5.  Novel 1-indanone Thiosemicarbazone Antiviral Candidates: Aqueous Solubilization and Physical Stabilization by Means of Cyclodextrins.

Authors:  Romina J Glisoni; Diego A Chiappetta; Albertina G Moglioni; Alejandro Sosnik
Journal:  Pharm Res       Date:  2011-10-06       Impact factor: 4.200

6.  Injectable in situ cross-linking hydrogels for local antifungal therapy.

Authors:  Sarah P Hudson; Robert Langer; Gerald R Fink; Daniel S Kohane
Journal:  Biomaterials       Date:  2009-11-26       Impact factor: 12.479

7.  Efficacy, Biodistribution, and Nephrotoxicity of Experimental Amphotericin B-Deoxycholate Formulations for Pulmonary Aspergillosis.

Authors:  Alicia López-Sánchez; Alba Pérez-Cantero; Carlos Torrado-Salmerón; Adela Martin-Vicente; Víctor García-Herrero; María Ángeles González-Nicolás; Alberto Lázaro; Alberto Tejedor; Santiago Torrado-Santiago; Juan José García-Rodríguez; Javier Capilla; Susana Torrado
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

8.  Safety, Tolerability, and Pharmacokinetics of a Novel Oral Amphotericin B Formulation (iCo-019) following Single-Dose Administration to Healthy Human Subjects: an Alternative Approach to Parenteral Amphotericin B Administration.

Authors:  Peter Hnik; Ellen K Wasan; Kishor M Wasan
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

9.  Assessing the Safety, Tolerability, Pharmacokinetics, and Biodistribution of Novel Oral Formulations of Amphotericin B following Single- and Multiple-Dose Administration to Beagle Dogs.

Authors:  Kishor M Wasan; Ellen K Wasan; Peter Hnik
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

Review 10.  Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy.

Authors:  Célia Faustino; Lídia Pinheiro
Journal:  Pharmaceutics       Date:  2020-01-01       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.